本研究旨在评估自体造血干细胞移植（AHCT）后12个月的常规肺功能测试（PFT）对淋巴瘤幸存者中临床显著性肺疾病的预测价值。在247名患者中，173名（70%）接受了BEAM（卡莫司汀，依托泊苷，阿糖胞苷，甲氨蝶呤）方案，49名（20%）接受了TBC（替扎那，布司佛，环磷酰胺）方案。基线PFT异常者为149例（60%）。自AHCT后，34例患者存在显著下降（DLCO或FEV1或FVC减少≥20%），其中中枢神经系统淋巴瘤组发生率最高（39%）。移植后临床显著性肺疾病的发生率仅为2%，且异常的术前和术后1年的PFT与临床肺疾病的发展之间没有关联。尽管本研究说明了治疗方案对PFT变化的影响，但并未证明预定的PFT对于鉴定AHCT后临床显著性肺疾病具有预测价值。

This study aims to evaluate the predictive value of routine pulmonary function testing (PFT) at the 12-month mark post-autologous hematopoietic cell transplant (AHCT) in identifying clinically significant lung disease in lymphoma survivors. In 247 patients, 173 (70%) received BEAM (carmustine, etoposide, cytarabine, melphalan), and 49 (20%) received TBC (thiotepa, busulfan, cyclophosphamide) conditioning regimens. Abnormal baseline PFT was noted in 149 patients (60%). Thirty-four patients had a significant decline (reduction of >/= 20% in DLCO or FEV1 or FVC) in post-AHCT PFT, with the highest incidence in the CNS lymphoma group (39%). The incidence of clinically significant lung disease post-transplant was low at 2% and there was no association between abnormal pre- and 1-year post-transplant PFTs with the development of clinical lung disease. While this study illustrates the impact of treatment regimens on PFT changes, it did not demonstrate a predictive value of scheduled PFTs in identifying clinically significant post-AHCT lung disease.